| Not Yet Recruiting | eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation NCT07469592 | University of Miami | N/A |
| Not Yet Recruiting | A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 ) NCT07101328 | Eli Lilly and Company | Phase 1 |
| Not Yet Recruiting | A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) NCT07519772 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15) NCT07454863 | Dizal Pharmaceuticals | Phase 1 |
| Not Yet Recruiting | High-Dose vs Standard Ergocalciferol for Vitamin D Normalization in Aggressive Non-Hodgkin Lymphoma NCT07366450 | Phramongkutklao College of Medicine and Hospital | N/A |
| Recruiting | A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies NCT07308132 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients NCT06133426 | Assistance Publique - Hôpitaux de Paris | N/A |
| Active Not Recruiting | Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers NCT07162181 | Eli Lilly and Company | Phase 2 |
| Recruiting | TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas NCT07082803 | Treeline Biosciences, Inc. | Phase 1 |
| Recruiting | Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving NCT06923397 | Dana-Farber Cancer Institute | N/A |
| Not Yet Recruiting | Study of the Association Between Fatigue Experienced by Patients and the Specific Side Effects of CART Cells, NCT06890091 | Assistance Publique - Hôpitaux de Paris | — |
| Enrolling By Invitation | A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring NCT06788509 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy NCT06510361 | Beth Israel Deaconess Medical Center | Phase 2 |
| Active Not Recruiting | A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory NCT06660563 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | Epcoritamab-CAR T Cells for Large B-cell Lymphomas NCT06458439 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Not Yet Recruiting | A Real-World Study on Extranodal Lymphoma NCT06573099 | Ruijin Hospital | — |
| Recruiting | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) NCT06343311 | Estrella Biopharma, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma NCT06470438 | Janssen Research & Development, LLC | Phase 1 |
| Not Yet Recruiting | This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly D NCT06427213 | Henan Cancer Hospital | Phase 2 |
| Recruiting | Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection NCT06541327 | Ruijin Hospital | — |
| Recruiting | Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignan NCT05800210 | University of Florida | Phase 2 |
| Recruiting | CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma NCT06101381 | University of Sao Paulo | Phase 1 / Phase 2 |
| Terminated | A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers NCT06120504 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Recruiting | A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies NCT06045910 | Cancer Research UK | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid ( NCT06139406 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors NCT06783816 | Shanxi Bethune Hospital | N/A |
| Active Not Recruiting | Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Tr NCT05968963 | University of Miami | N/A |
| Recruiting | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in NCT06022029 | OncoNano Medicine, Inc. | Phase 1 |
| Unknown | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma NCT06149169 | Shanghai Ming Ju Biotechnology Co., Ltd. | Phase 2 |
| Terminated | Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma NCT05618366 | Weill Medical College of Cornell University | Phase 1 |
| Recruiting | DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT05824585 | Dizal Pharmaceuticals | Phase 1 |
| Withdrawn | A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT05431179 | Oncternal Therapeutics, Inc | Phase 3 |
| Active Not Recruiting | A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or NCT05515406 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL) NCT06170216 | Fudan University | — |
| Recruiting | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or R NCT05442515 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation NCT04935684 | University Hospital, Clermont-Ferrand | Phase 2 |
| Active Not Recruiting | Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomi NCT05556720 | Monash University | Phase 3 |
| Completed | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolum NCT05255601 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant NCT05540340 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With No NCT05424822 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma NCT05421663 | Janssen Research & Development, LLC | Phase 1 / Phase 2 |
| Completed | The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors NCT05131815 | Cedars-Sinai Medical Center | N/A |
| Completed | A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1) NCT05844956 | Dizal Pharmaceuticals | Phase 1 / Phase 2 |
| Active Not Recruiting | Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG NCT04892667 | Assistance Publique - Hôpitaux de Paris | N/A |
| Enrolling By Invitation | Long-Term Follow-up Study NCT05332054 | Caribou Biosciences, Inc. | — |
| Terminated | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With NCT05219513 | Hoffmann-La Roche | Phase 1 |
| Active Not Recruiting | Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells NCT04911478 | Adicet Therapeutics | — |
| Terminated | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutatio NCT05153330 | Biomea Fusion Inc. | Phase 1 |
| Terminated | A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT04860466 | Celgene | Phase 1 |
| Completed | Fitness Assessment in Young Adults Recovered From Lymphoma NCT05188755 | University Hospital, Clermont-Ferrand | N/A |
| Unknown | Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL NCT05557903 | Lanzhou Institute of Biological Products Co., Ltd | Phase 1 |
| Completed | A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants NCT05176873 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Phase 1 |
| Active Not Recruiting | Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector C NCT04975555 | University of Alabama at Birmingham | Phase 2 |
| Terminated | Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study NCT04982471 | Celgene | — |
| Unknown | A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors NCT05150405 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Active Not Recruiting | Study of Oral LOXO-338 in Patients With Advanced Blood Cancers NCT05024045 | Eli Lilly and Company | Phase 1 |
| Completed | A Study of LP-118 in Patients With Advanced Tumors NCT05025358 | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 1 |
| Recruiting | Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus P NCT04460235 | Poitiers University Hospital | Phase 4 |
| Active Not Recruiting | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell NCT05020678 | Nkarta, Inc. | Phase 1 |
| Enrolling By Invitation | Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO Study NCT04996706 | Mayo Clinic | — |
| Completed | A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL NCT04876092 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANT NCT04637763 | Caribou Biosciences, Inc. | Phase 1 |
| Completed | Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell NCT05784415 | AIDS Malignancy Consortium | — |
| Completed | A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) NCT04849416 | Eli Lilly and Company | Phase 2 |
| Completed | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies NCT04772989 | Arcus Biosciences, Inc. | Phase 1 |
| Terminated | A Phase 1 Study of ADI-001 in B Cell Malignancies NCT04735471 | Adicet Therapeutics | Phase 1 |
| Completed | A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leu NCT04657224 | Janssen Research & Development, LLC | Phase 1 |
| Completed | A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed NCT04434196 | Celgene | Phase 1 |
| Unknown | Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL NCT04638270 | Xinqiao Hospital of Chongqing | EARLY_Phase 1 |
| Completed | A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) NCT04540796 | Janssen Research & Development, LLC | Phase 1 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent NCT04245839 | Celgene | Phase 2 |
| Completed | A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia NCT04210219 | Janssen Research & Development, LLC | Phase 1 |
| Completed | CAR-37 T Cells in Hematologic Malignancies NCT04136275 | Marcela V. Maus, M.D.,Ph.D. | Phase 1 |
| Completed | A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or NCT04231747 | Juno Therapeutics, a Subsidiary of Celgene | Phase 1 |
| Terminated | Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL NCT04342117 | SecuraBio | — |
| Completed | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL NCT04030195 | Precision BioSciences, Inc. | Phase 1 / Phase 2 |
| Completed | An Individualized Physical Activity Program in Patients Over 65 Years With Hematologic Malignancies NCT04052126 | Centre Leon Berard | N/A |
| Completed | Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With A NCT04089527 | Celgene | Phase 1 |
| Terminated | A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lympho NCT04074330 | Takeda | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Co NCT04077723 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Unknown | Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphom NCT04083079 | Ruijin Hospital | Phase 4 |
| Unknown | Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma NCT03921879 | Oncotartis, Inc. | Phase 1 |
| Unknown | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma NCT04089215 | Shanghai Ming Ju Biotechnology Co., Ltd. | Phase 2 |
| Active Not Recruiting | A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Par NCT03930953 | Celgene | Phase 1 / Phase 2 |
| Completed | A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CL NCT03900598 | Janssen Research & Development, LLC | Phase 1 |
| Withdrawn | A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL) NCT03772288 | Calithera Biosciences, Inc | Phase 1 |
| Unknown | Biomarkers in Primary Sjögren's Syndrome NCT03765593 | National Council of Scientific and Technical Research, Argentina | — |
| Completed | A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymp NCT03744676 | Juno Therapeutics, a Subsidiary of Celgene | Phase 2 |
| Completed | A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Tr NCT03575351 | Celgene | Phase 3 |
| Terminated | A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B- NCT03743246 | Celgene | Phase 1 / Phase 2 |
| Completed | Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475 NCT03598608 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Completed | Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma NCT03682796 | Triphase Research and Development III Corp. | Phase 1 |
| Completed | Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) NCT03483103 | Juno Therapeutics, a Subsidiary of Celgene | Phase 2 |
| Completed | Symbenda Post-Marketing Surveillance (PMS) NCT02434484 | Eisai Korea Inc. | — |
| Completed | Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin NCT03484702 | Celgene | Phase 2 |
| Completed | Copanlisib Chinese PK Study NCT03498430 | Bayer | Phase 1 |
| Active Not Recruiting | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression NCT03480360 | Dartmouth-Hitchcock Medical Center | Phase 3 |
| Completed | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD NCT03448393 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) NCT03297606 | Canadian Cancer Trials Group | Phase 2 |
| Withdrawn | A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Ther NCT03369964 | Hoffmann-La Roche | Phase 1 |
| Completed | A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin L NCT03357627 | Calithera Biosciences, Inc | Phase 1 |
| Unknown | Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma ( NCT03373019 | Fudan University | Phase 2 |
| Completed | A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies NCT03310619 | Celgene | Phase 1 / Phase 2 |
| Completed | Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients NCT03366272 | Universität des Saarlandes | Phase 2 / Phase 3 |
| Completed | Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System Lymphoma NCT03188354 | Norwegian University of Science and Technology | N/A |
| Completed | Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell NCT03019055 | Medical College of Wisconsin | Phase 1 |
| Completed | An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) NCT03289182 | Hoffmann-La Roche | — |
| Completed | FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma NCT01410630 | Jonsson Comprehensive Cancer Center | — |
| Terminated | A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL) NCT03238651 | Calithera Biosciences, Inc | Phase 1 |
| Terminated | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects NCT03220347 | Celgene | Phase 1 |
| Active Not Recruiting | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. NCT03229200 | Pharmacyclics Switzerland GmbH | Phase 4 |
| Completed | Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell NCT02257242 | Brown University | Phase 1 |
| Unknown | Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation NCT03244930 | Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 |
| Unknown | Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCL NCT03958916 | Sun Yat-sen University | — |
| Unknown | A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With LBL NCT03971318 | Sun Yat-sen University | — |
| Unknown | Precision Exercise in Children With Malignant Hemopathies NCT04090268 | University of Milano Bicocca | N/A |
| Terminated | A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib fo NCT02954406 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Recruiting | Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III NCT03117036 | Samsung Medical Center | — |
| Completed | Using Telephone Counselling to Improve Exercise Participation in Hematologic Cancer Survivors NCT03052777 | University of Alberta | N/A |
| Terminated | Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study NCT03733249 | Bellicum Pharmaceuticals | Phase 1 / Phase 2 |
| Unknown | The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas NCT03000738 | Peking Union Medical College Hospital | — |
| Completed | Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine NCT02996773 | University of Arizona | Phase 1 |
| Unknown | PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia NCT02996617 | Shandong Provincial Hospital | Phase 4 |
| Terminated | Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma NCT02867618 | Columbia University | Phase 1 / Phase 2 |
| Terminated | A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-H NCT02875223 | Celgene | Phase 1 |
| Active Not Recruiting | Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL NCT02690545 | UNC Lineberger Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Terminated | A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory NCT02703272 | Janssen Research & Development, LLC | Phase 3 |
| Active Not Recruiting | Administration of T Lymphocytes for Prevention of Relapse of Lymphomas NCT02663297 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Completed | Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab NCT02747043 | Amgen | Phase 3 |
| Completed | Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib NCT02613598 | University of Michigan Rogel Cancer Center | Phase 1 |
| Recruiting | Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols NCT02682667 | National Cancer Institute (NCI) | — |
| Recruiting | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality NCT02693535 | American Society of Clinical Oncology | Phase 2 |
| Unknown | BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma NCT02836639 | Pusan National University Hospital | Phase 2 |
| Terminated | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphom NCT02626455 | Bayer | Phase 3 |
| Completed | Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodg NCT02581878 | Bayer | Phase 1 |
| Terminated | 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients NCT02602067 | sigma-tau i.f.r. S.p.A. | Phase 1 |
| Completed | Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma NCT06190457 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Completed | Phase III Copanlisib in Rituximab-refractory iNHL NCT02369016 | Bayer | Phase 3 |
| Completed | A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With NCT02500407 | Genentech, Inc. | Phase 1 / Phase 2 |
| Terminated | A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and No NCT02509039 | Celgene | Phase 1 |
| Completed | GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma NCT02499003 | Johannes Gutenberg University Mainz | Phase 2 |
| Completed | Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) NCT02367040 | Bayer | Phase 3 |
| Not Yet Recruiting | Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma NCT02497898 | The First People's Hospital of Changzhou | Phase 2 |
| Completed | A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapse NCT02417285 | Celgene | Phase 1 |
| Completed | Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma NCT02187133 | University of California, San Francisco | Phase 1 |
| Terminated | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors NCT02440685 | Asana BioSciences | Phase 1 / Phase 2 |
| Completed | Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL NCT02342665 | Bayer | Phase 1 / Phase 2 |
| Terminated | BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma NCT02417129 | Boehringer Ingelheim | Phase 3 |
| Completed | Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimi NCT04971304 | Catherine M. Lockhart | — |
| Terminated | Safety Study of SEA-CD40 in Cancer Patients NCT02376699 | Seagen Inc. | Phase 1 |
| Unknown | ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma NCT02431403 | Pusan National University Hospital | Phase 1 / Phase 2 |
| Completed | Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastin NCT03480087 | A.O.U. Città della Salute e della Scienza | — |
| Completed | Molecular and Whole-body MR Imaging in Lymphomas NCT02389101 | Turku University Hospital | N/A |
| Completed | Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for NCT02098109 | Washington University School of Medicine | Phase 2 |
| Withdrawn | B-Cell Hematologic Malignancy Vaccination Registry NCT02298816 | Wake Forest University Health Sciences | — |
| Terminated | Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant NCT02065869 | Bellicum Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Foll NCT01996865 | Celgene | Phase 3 |
| Active Not Recruiting | Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant NCT03301168 | Bellicum Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) NCT01969435 | Washington University School of Medicine | Phase 2 |
| Completed | Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Eit NCT02038933 | Bristol-Myers Squibb | Phase 2 |
| Completed | A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, a NCT01992653 | Genentech, Inc. | Phase 1 / Phase 2 |
| Completed | Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicula NCT01938001 | Celgene | Phase 3 |
| Completed | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Parti NCT02055820 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Completed | Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreate NCT01754857 | University of Wisconsin, Madison | Phase 2 |
| Completed | MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of NCT01987505 | Hoffmann-La Roche | Phase 3 |
| Completed | Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim NCT03057418 | Biointegrator LLC | Phase 1 |
| Completed | Preventing Stem Cell Transplant Complications With a Blood Separator Machine NCT01866839 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 / Phase 2 |
| Completed | Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, In NCT01660451 | Bayer | Phase 2 |
| Completed | Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant NCT01720264 | Sherif S. Farag | Phase 2 |
| Recruiting | Tissue Collection for Studies of Lymph Cancer NCT01676805 | National Cancer Institute (NCI) | — |
| Terminated | Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transp NCT01745354 | Robert Lowsky | Phase 1 |
| Terminated | Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma NCT01555853 | Washington University School of Medicine | Phase 1 |
| Completed | Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma NCT02072967 | Astellas Pharma Europe B.V. | — |
| Completed | Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell NCT01660607 | Stanford University | Phase 1 / Phase 2 |
| Withdrawn | Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP NCT01843868 | Australasian Leukaemia and Lymphoma Group | N/A |
| Completed | IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukem NCT01534715 | ImmunoGen, Inc. | Phase 1 |
| Completed | BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) NCT01403948 | Boehringer Ingelheim | Phase 1 |
| Completed | A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma NCT01421667 | Seagen Inc. | Phase 2 |
| Completed | Study of Lymphoma in Asia NCT01584141 | National Cancer Institute (NCI) | — |
| Completed | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab NCT01307267 | Pfizer | Phase 1 |
| Withdrawn | Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas NCT01263418 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Completed | Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodg NCT01294579 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patien NCT01232556 | Pfizer | Phase 3 |
| Completed | Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors NCT01158118 | Washington University School of Medicine | Phase 2 |
| Terminated | Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma NCT01186458 | Hoosier Cancer Research Network | Phase 2 |
| Completed | Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease NCT00871702 | Washington University School of Medicine | Phase 1 |
| Completed | Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease NCT01155817 | Stanford University | Phase 1 |
| Terminated | MSC and HSC Coinfusion in Mismatched Minitransplants NCT01045382 | University of Liege | Phase 2 |
| Terminated | Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin NCT01121120 | Tarix Pharmaceuticals | Phase 2 |
| Completed | Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM) NCT01196520 | National Cancer Institute (NCI) | — |
| Terminated | An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completi NCT01090414 | Gilead Sciences | Phase 1 / Phase 2 |
| Completed | Cardiac Safety Study of Brentuximab Vedotin (SGN-35) NCT01026233 | Seagen Inc. | Phase 1 |
| Completed | Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) NCT01026415 | Seagen Inc. | Phase 1 |
| Completed | A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma NCT01015911 | Seagen Inc. | Phase 1 |
| Terminated | Pilot Study of Unrelated Cord Blood Transplantation NCT00916045 | King's College Hospital NHS Trust | Phase 2 |
| Terminated | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refract NCT00963495 | University Health Network, Toronto | Phase 1 |
| Completed | A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study NCT00947856 | Seagen Inc. | Phase 2 |
| Terminated | Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical NCT01050946 | Medical College of Wisconsin | Phase 2 |
| Active Not Recruiting | Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma NCT00882895 | Washington University School of Medicine | Phase 2 |
| Completed | Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma NCT00896493 | Stanford University | Phase 2 |
| Completed | Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma NCT00901069 | Shams Shakil | Phase 1 |
| Completed | Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN NCT00912223 | Medical College of Wisconsin | Phase 2 |
| Completed | Sitagliptin Umbilical Cord Blood Transplant Study NCT00862719 | Indiana University School of Medicine | Phase 2 |
| Completed | A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma NCT00866047 | Seagen Inc. | Phase 2 |
| Completed | A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas NCT00880581 | Ronald Levy | Phase 2 |
| Completed | Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma NCT00733824 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Completed | B-Receptor Signaling in Cardiomyopathy NCT01135849 | Daniel Bernstein | — |
| Completed | A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors NCT00779584 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma NCT00903890 | University of Rochester | — |
| Completed | Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma NCT00724984 | Pharmacyclics LLC. | Phase 1 / Phase 2 |
| Completed | Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL NCT00655837 | Seagen Inc. | Phase 1 |
| Completed | Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma NCT00644124 | Sanofi | Phase 1 |
| Terminated | A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignan NCT00649584 | Seagen Inc. | Phase 1 |
| Unknown | Functional Assessment of Cancer Therapy - Bone Marrow Transplant NCT01490957 | King Faisal Specialist Hospital & Research Center | — |
| Completed | Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL NCT00546793 | Gilead Sciences | Phase 1 / Phase 2 |
| Completed | Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients NCT00562224 | Pharmacyclics LLC. | Phase 1 |
| Completed | Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas NCT00572637 | Ethical Oncology Science | Phase 1 |
| Terminated | T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE NCT00578461 | Baylor College of Medicine | N/A |
| Unknown | High-dose Chemotherapy and Stem Cell Transplantation for Central Nervous System (CNS) Relapse of Aggressive Ly NCT01148173 | Charite University, Berlin, Germany | Phase 2 |
| Withdrawn | A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma NCT00538096 | MedImmune LLC | Phase 1 |
| Completed | Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing NCT00534989 | King Faisal Specialist Hospital & Research Center | N/A |
| Terminated | A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients Wit NCT00529503 | Seagen Inc. | Phase 2 |
| Completed | Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma NCT00536835 | GlaxoSmithKline | Phase 1 |
| Completed | A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin NCT00500058 | GlaxoSmithKline | Phase 1 |
| Completed | Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Pati NCT00553943 | Lymphoma Study Association | Phase 2 |
| Terminated | Therapeutic Intensification of HIV-associated Non-Hodgkin's Lymphoma by Peripheral Blood Cell Transplantation NCT00432419 | French National Agency for Research on AIDS and Viral Hepatitis | Phase 1 / Phase 2 |
| Terminated | Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy NCT00490490 | Stanford University | Phase 2 |
| Completed | Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL) NCT00426855 | Peter Moosmann | Phase 1 / Phase 2 |
| Terminated | Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma NCT00481832 | Stanford University | Phase 2 |
| Unknown | Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases NCT00538551 | King Faisal Specialist Hospital & Research Center | — |
| Completed | Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma NCT00435916 | Seagen Inc. | Phase 2 |
| Terminated | CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's NCT00455897 | Massachusetts General Hospital | Phase 2 |
| Completed | Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies NCT00430846 | Seagen Inc. | Phase 1 |
| Completed | Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630) NCT00871910 | Merck Sharp & Dohme LLC | Phase 1 |
| Terminated | Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT NCT00482053 | Stanford University | Phase 2 |
| Completed | Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) NCT00871663 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT NCT00350181 | Stanford University | Phase 2 |
| Terminated | VELCADE,Rituximab,Cyclophosphamide and Decadron NCT00413959 | Oncology Specialists, S.C. | Phase 2 |
| Unknown | Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment NCT00324467 | British Columbia Cancer Agency | Phase 2 |
| Completed | Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma NCT00347971 | ZymoGenetics | Phase 1 |
| Unknown | A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell No NCT00333008 | The Alvin and Lois Lapidus Cancer Institute | Phase 2 |
| Active Not Recruiting | Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) NCT00368082 | Baylor College of Medicine | Phase 1 |
| Completed | Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell L NCT00283985 | University Hospital, Limoges | Phase 2 |
| Terminated | A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantati NCT00275262 | Abbott | Phase 2 |
| Completed | Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCT NCT00329030 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 |
| Completed | Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL) NCT00156013 | Oncology Specialists, S.C. | Phase 1 / Phase 2 |
| Withdrawn | A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Re NCT00319332 | GlaxoSmithKline | Phase 3 |
| Terminated | Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas. NCT00354822 | A.O. Ospedale Papa Giovanni XXIII | Phase 2 |
| Terminated | Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Ho NCT00367497 | Keio University | Phase 2 |
| Completed | Assessment of Treatment Response Using PET/CT Scanner - Non Hodgkin's Lymphoma NCT00188929 | University Health Network, Toronto | Phase 2 |
| Completed | A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or C NCT00412321 | Centocor, Inc. | Phase 1 |
| Completed | Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma NCT00185731 | Dean Felsher | Phase 2 |
| Completed | Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients NCT00103610 | Genzyme, a Sanofi Company | Phase 3 |
| Completed | AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regi NCT00396266 | Genzyme, a Sanofi Company | Phase 2 |
| Terminated | A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced C NCT00147485 | Pfizer | Phase 1 |
| Completed | Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Pati NCT00268983 | GlaxoSmithKline | Phase 3 |
| Completed | Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients NCT00322842 | Genzyme, a Sanofi Company | Phase 2 |
| Completed | A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cance NCT00141297 | Pfizer | Phase 1 |
| Completed | BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) NCT00088530 | CTI BioPharma | Phase 3 |
| Completed | Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transpla NCT00534820 | King Faisal Specialist Hospital & Research Center | N/A |
| Completed | Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma ( NCT00094848 | Human Genome Sciences Inc. | Phase 2 |
| Completed | 90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistan NCT00186589 | Stanford University | Phase 1 |
| Completed | Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malign NCT00241358 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Completed | Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lympho NCT00322387 | Genzyme, a Sanofi Company | Phase 2 |
| Recruiting | Family Study of Lymphoproliferative Disorders NCT00626496 | Mayo Clinic | — |
| Completed | Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma NCT00240565 | GlaxoSmithKline | Phase 2 |
| Completed | Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma NCT00322491 | Genzyme, a Sanofi Company | Phase 2 |
| Completed | An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphom NCT00097565 | Genentech, Inc. | — |
| Completed | Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma NCT00117156 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Iodine I 131 Tositumomab NCT00240578 | GlaxoSmithKline | — |
| Completed | Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma NCT00186355 | Stanford University | N/A |
| Completed | Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Tositumomab and/or Iodine I 131 Tositum NCT00240591 | GlaxoSmithKline | — |
| Completed | ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia NCT00114348 | Charite University, Berlin, Germany | Phase 4 |
| Completed | Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies NCT00145613 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma NCT00168727 | Biogen | Phase 4 |
| Completed | Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma NCT00061672 | Abbott | Phase 2 |
| Completed | Randomized Double Cord Blood Transplant Study NCT00067002 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Reproducibility of an Immobilization Device (BodyFIX) - Hodgkins/Lymphoma NCT00232440 | University Health Network, Toronto | Phase 1 / Phase 2 |
| Completed | Music Imagery for Patients Receiving Chemotherapy for Leukemia or Non-Hodgkin's Lymphoma NCT00082303 | National Center for Complementary and Integrative Health (NCCIH) | Phase 1 / Phase 2 |
| Completed | Meaning-Centered Psychotherapy in Advanced Cancer NCT00067288 | National Center for Complementary and Integrative Health (NCCIH) | Phase 2 |
| Completed | Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma NCT00044551 | Bayer | Phase 2 |
| Completed | Genome Expression in Lymphoma, Leukemia and Multiple Myeloma NCT00339963 | National Cancer Institute (NCI) | — |
| Unknown | Helicobacter - Lymphoma - Radiation Part I: Eradication, Part II: Radiation NCT00154440 | Technische Universität Dresden | Phase 3 |
| Completed | Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma NCT00185393 | Bayer | Phase 3 |
| Completed | Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS NCT00025662 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment NCT00398372 | Stanford University | N/A |
| Completed | A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Ch NCT00261677 | Ortho Biotech Products, L.P. | Phase 3 |
| Completed | Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP NCT01868035 | GlaxoSmithKline | Phase 2 |
| Completed | High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma NCT00186394 | Stanford University | Phase 2 |
| Completed | Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Gr NCT01663714 | GlaxoSmithKline | Phase 2 |
| Completed | Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than NCT00992758 | GlaxoSmithKline | Phase 1 |
| Completed | Ultrasound Biomicroscopy - Apoptosis NCT00188370 | University Health Network, Toronto | Phase 2 |
| Recruiting | Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease NCT00398177 | Stanford University | — |
| Completed | A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory NCT01573000 | GlaxoSmithKline | Phase 2 |
| Completed | Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma NCT00268203 | GlaxoSmithKline | Phase 2 |
| Completed | Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tos NCT00933335 | GlaxoSmithKline | Phase 2 |
| Completed | Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rit NCT00996593 | GlaxoSmithKline | Phase 2 |
| Completed | Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas Tha NCT00950755 | GlaxoSmithKline | Phase 2 |
| Completed | Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibo NCT00938041 | GlaxoSmithKline | Phase 2 |
| Completed | Large Cell Lymphoma Pilot Study III NCT00187070 | St. Jude Children's Research Hospital | N/A |